ClinicalTrials.gg
CompletedNCT06270836GLOW2Updated May 13, 2026

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

A Phase 3 interventional study of Tarcocimab and Sham injection in Diabetic Retinopathy, sponsored by Kodiak Sciences Inc. Completed at 39 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Kodiak Sciences Inc · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 54 under way, 6 of them phase 3. Diabetic Retinopathy · United States.

Enrollment
54th of 196
255 · median 72
Started
2024
with 10 others
Phase 3
31 of 267
4 open now
Registered
230th of 267
by date

Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 54th largest by enrollment of the 196 interventional ones that give a count, is one of 11 that started in 2024, is one of 31 in phase 3, and was the 230th registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 267 studies in Diabetic Retinopathy with a site in United States, or all of them as a file.
02

Study summary

This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with DR.

Read the detailed description

This is a prospective, randomized, double-masked, two-arm, multi-center Phase 3 study to demonstrate that tarcocimab 5 mg is superior to sham treatment, with respect to the proportion of eyes improving from baseline at Week 48 in participants with DR.

03

Conditions studied

  • Diabetic Retinopathy

Keywords

  • Diabetic Retinopathy
  • NPDR
  • KSI-301
  • VEGF
  • Anti-VEGF
  • Vascular Endothelial Growth Factor
  • Antibody Biopolymer Conjugate
  • Retinal Degeneration
  • Retinal Diseases
  • Eye Diseases
  • Retinopathy
  • Vision Disorders
  • Kodiak
  • Tarcocimab Tedromer
  • Tarcocimab
  • Diabetic Eye Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed prior to participation in the study.
  • Type 1 or 2 diabetes mellitus and of ≤12%.
  • DR in the Study Eye (DRSS as determined by the reading center based on color fundus photographs), who have not previously received intravitreal medications for DR or DME, and in whom pan-retinal photocoagulation (PRP) can be safely deferred for at least 6 months per the Investigator.
  • CST ≤320 microns and a BCVA ETDRS letter score in the Study Eye of ≥69 letters (approximate Snellen equivalent of 20/40 or better) in the Study Eye at screening and confirmed at Day 1; OR
  • CST >320 and ≤350 microns and a BCVA ETDRS letter score in the Study Eye of ≥79 letters (approximate Snellen equivalent of 20/25 or better) in the Study Eye at screening and confirmed at Day 1.

Exclusion criteria

Exclusion Criteria:

  • Prior PRP in the Study Eye.
  • Current anterior segment neovascularization (ASNV), vitreous hemorrhage, or tractional retinal detachment in the Study Eye.
  • Prior intravitreal anti-VEGF treatment in the Study Eye for DR or DME within the last twelve (12) months prior to Day 1.
  • Prior intravitreal or periocular in the Study Eye for DR or DME within the last twelve (12) months prior to Day 1.
  • Prior use of an intravitreal treatment for DR or DME in the Study Eye.
  • History of vitreoretinal surgery in the Study Eye.
  • History of uveitis in either eye.
  • Cataract in the Study Eye that in the judgment of the Investigator is expected to require surgical extraction within 12 months of screening.
  • Significant media opacities, including cataract, in the Study Eye that might interfere with visual acuity, assessment of safety, OCT, or FP.
  • Any history or evidence of a concurrent ocular condition present in the Study Eye, that in the opinion of the Investigator could require either medical or surgical intervention or alter visual acuity during the study.
  • Active or suspected ocular or periocular infection or inflammation.
  • Women who are pregnant or lactating or intending to become pregnant during the study.
  • History of a medical condition that, in the judgment of the Investigator, would preclude scheduled study visits, completion of the study, or a safe administration of investigational product.
  • Recent history (within the 6 months prior to screening) of myocardial infarction, stroke, , acute congestive heart failure or any acute coronary event.
  • Uncontrolled blood pressure defined as a systolic value ≥ 180 mmHg or diastolic value ≥ 100 mmHg while at rest.
  • Other protocol-specified exclusion criteria may apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
255 participants (actual)

Study arms

  • Experimental
    Tarcocimab 5 mg (Treatment Group A)

    Tarcocimab 5 mg via intravitreal injection at Day 1, Week 4, Week 8, Week 20, and Week 44.

    Drug: Tarcocimab

  • Sham comparator
    Treatment Group B

    Sham injection on the same schedule as Treatment Group A

    Other: Sham injection

Interventions

  • DrugTarcocimab

    Intravitreal injection

    Also known as: Tarcocimab tedromer, KSI-301

  • OtherSham injection

    The sham injection is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It is performed to maintain masking of the study.

06

What researchers measure

Primary outcomes

  1. Proportion of eyes improving ≥2 steps on the Early Treatment Diabetic Retinopathy Diabetic Retinopathy Severity Scale (ETDRS DRSS)

    Early Treatment Diabetic Retinopathy Diabetic Retinopathy Severity Scale (ETDRS DRSS), on a scale from 10 to 90, where lower scores represent better outcomes.

    Time frame: Day 1 to Week 48

Secondary outcomes

  1. Proportion of eyes developing a Sight-Threatening Complication(s) of diabetic retinopathy

    Sight-threatening complications include diabetic macular edema, new or worsening proliferative diabetic retinopathy, and anterior segment neovascularization

    Time frame: Day 1 to Week 48

  2. Proportion of eyes improving ≥3 steps on Early Treatment Diabetic Retinopathy Diabetic Retinopathy Severity Scale (ETDRS DRSS)

    Early Treatment Diabetic Retinopathy Diabetic Retinopathy Severity Scale (ETDRS DRSS), on a scale from 10 to 90, where lower scores represent better outcomes.

    Time frame: Day 1 to Week 48

07

Study locations

39 sites
  • Retina Associates SW
    Tucson, Arizona 85704, United States
  • Retina Consultants of Orange County
    Fullerton, California 92835, United States
  • Global Research Management, Inc. - Lugene Eye Institute
    Glendale, California 91204, United States
  • Retinal Consultants Medical Group, Inc.
    Modesto, California 95356, United States
  • Retina Consultants of Southern California
    Redlands, California 92374, United States
  • Retinal Consultants Medical Group, Inc.
    Sacramento, California 95825, United States
  • Retina Group of New England, PC
    Waterford, Connecticut 06385, United States
  • Retina Group of Florida
    Fort Lauderdale, Florida 33308, United States
  • Florida Eye Associates
    Melbourne, Florida 32901, United States
  • Center for Retina and Macular Disease
    Winter Haven, Florida 33880, United States
  • Southeast Retina Center
    Augusta, Georgia 30909, United States
  • Springfield Clinic LLP
    Springfield, Illinois 62703, United States
  • Associated Vitreoretinal and Uveitis Consultants
    Carmel, Indiana 46290, United States
  • Cumberland Valley Retina Consultants
    Hagerstown, Maryland 21740, United States
  • Retina Consultants of Nevada
    Henderson, Nevada 89052, United States
  • Envision Ocular, LLC
    Bloomfield, New Jersey 07003, United States
  • Asheville Eye Associates
    Asheville, North Carolina 28803, United States
  • North Carolina Retina Associates (Cary)
    Cary, North Carolina 27511, United States
  • North Carolina Retina Associates (Wake Forest)
    Wake Forest, North Carolina 27587, United States
  • Cascade Medical Research Institute
    Springfield, Oregon 97477, United States
  • Erie Retina Research
    Erie, Pennsylvania 16507, United States
  • Charleston Neuroscience Institute
    Charleston, South Carolina 29414, United States
  • Charles Retina Institute
    Germantown, Tennessee 38138, United States
  • Southeastern Retina Associates PC
    Knoxville, Tennessee 37922, United States
  • Retina Research Institute of Texas
    Abilene, Texas 79606, United States
  • Panhandle Eye Group, LLP. - Southwest Retina Specialists
    Amarillo, Texas 79106, United States
  • Austin Retina Associates, PLLC (Austin)
    Austin, Texas 78705-1169, United States
  • Austin Research Center for Retina
    Austin, Texas 78705, United States
  • Retina Consultants of Texas (Bellaire)
    Bellaire, Texas 77401, United States
  • Star Vision Research
    Burleson, Texas 76028, United States
  • Retina Consultants of Texas (Katy)
    Katy, Texas 77494, United States
  • Texas Retina Associates
    Plano, Texas 75075, United States
  • Austin Retina Associates, PLLC (Round Rock)
    Round Rock, Texas 78681, United States
  • Retina Consultants of Texas (San Antonio)
    San Antonio, Texas 78240, United States
  • Retina Consultants of Texas (Woodlands)
    The Woodlands, Texas 77384, United States
  • Piedmont Eye Center
    Lynchburg, Virginia 24502, United States
  • Pacific Northwest Retina (Bellevue)
    Bellevue, Washington 98004, United States
  • Spokane Eye Clinical Research
    Spokane, Washington 99204, United States
  • Emanuelli Research & Development Center, LLC
    Arecibo, 00612, Puerto Rico
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Feb 2026, 21 months.

Of 21 phase 3 interventional studies under Diabetic Retinopathy, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 41. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2024
First posted
Feb 21, 2024
StartActual
May 1, 2024
Primary completionActual
Feb 13, 2026
CompletionActual
Feb 13, 2026
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06270836
Lead sponsor
Kodiak Sciences Inc
Responsible party
Sponsor
First posted
Feb 21, 2024
Start date
May 1, 2024
Primary completion
Feb 13, 2026
Completion
Feb 13, 2026
Last update
May 13, 2026

Study contacts

Pablo Velazquez-Martin, MD
study director · Kodiak Sciences Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion